Company Overview
Adial Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the development of therapeutics designed for the treatment or prevention of addiction and related disorders. The company functions within the Healthcare sector, specifically inside the Biotechnology industry, which typically involves high-risk, high-reward research and development cycles before products reach commercialization. With a market capitalization of $2.34M and a workforce consisting of 5 employees, Adial maintains a very small operational footprint typical of early-stage clinical entities. The market cap figure of $2.34M indicates that the company is a micro-cap entity with limited market penetration, while the N/A revenue status confirms that the company has not yet generated significant commercial sales, positioning it strictly in the pre-revenue or early commercial phase of its lifecycle.
Financial Health
The company reported a net income of $-7,977,171 and an EBITDA of $-7,798,897 for the trailing twelve months, while revenue figures are listed as N/A. The substantial gap between the N/A revenue and the significant net loss reveals a cost structure dominated by research and development expenses and general administrative costs rather than commercial operating expenses. Free cash flow stands at $-3,768,275, indicating that the company is burning cash rapidly, which suggests limited financial flexibility without continued external capital raises or funding injections. All three margins—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet achieved profitability and is operating at a loss on its financial statements. The company holds $5.88M in cash against N/A in debt, resulting in a debt-to-equity ratio that is N/A due to the absence of recorded debt figures. This cash position relative to the cash burn rate provides a runway for operations, suggesting the balance sheet is currently un-leveraged rather than conservatively managed with existing debt. The current ratio is 4.42, which indicates a strong ability to meet short-term obligations with its liquid assets, providing a buffer against liquidity risks despite the ongoing losses. Return on Equity is -170.7% and Return on Assets is -83.2%, metrics that reveal management is currently generating negative returns on the capital invested and the assets held, reflecting the inherent losses of a clinical-stage biotechnology company that has not yet commercialized its lead product.
Valuation Assessment
The P/E Ratio (TTM) is N/A because the company is not yet profitable, while the Forward P/E is listed as -0.34, a metric that implies expected earnings remain negative in the near future. The price-to-book ratio is 0.35, which indicates that the market values the company at a significant discount to its book value, a common occurrence for biotechnology firms with unproven assets and no historical earnings. The price-to-sales ratio is N/A, and the EV/EBITDA stands at 0.45; these alternative valuation metrics suggest that the company is valued based on enterprise value relative to negative earnings, highlighting the speculative nature of the investment. The 52-week high is $30.25 and the 52-week low is $1.54, meaning the stock has experienced extreme volatility, though the current price sits at a level that reflects the high uncertainty surrounding the Phase 3 clinical trials of its lead product. The beta value is 1.32, which means the stock price is expected to be 32% more volatile than the broader market, exposing investors to higher risk during periods of market fluctuation.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, reflecting the company's status as a pre-revenue entity where historical growth rates cannot be calculated. Since the company has no revenue, it is impossible to compare earnings growth to revenue growth, as the earnings are entirely driven by the costs of developing the lead product AD04. As a non-dividend payer, the company reinvests its remaining resources into research and development rather than distributing cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. The overall growth and income profile is defined by total reliance on future clinical trial success and external financing, with no current income generation or historical growth trajectory available for analysis.